Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 17/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777593 | 0.89 | PPARD (0.43) | PPARDPPARGPPARA | |
| SCHEMBL1776847 | 0.87 | PPARD (0.62) | PPARDPPARA | |
| SCHEMBL1777082 | 0.86 | PPARD (0.51) | PPARDPPARGPPARA | |
| SCHEMBL14419934 | 0.86 | PPARD (0.62) | PPARDPPARA | |
| SCHEMBL1775862 | 0.85 | PPARD (0.59) | PPARDPPARGPPARA | |
| SCHEMBL1778482 | 0.80 | KDM4E (0.52) | PPARDPPARGPPARA | |
| SCHEMBL2822164 | 0.79 | PPARD (0.70) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL1778711 | 0.78 | FFAR1 (0.62) | PPARDPPARGFFAR1 | |
| SCHEMBL3385737 | 0.78 | PPARD (0.69) | PPARDPPARGPPARAFFAR1MCL1 | |
| SCHEMBL1780580 | 0.77 | PPARD (0.52) | PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943612-B2 | Compounds that modulate PPAR activity, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943612-B2 | Compounds that modulate PPAR activity, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC | 2009-02-19 | — | — | US | disclosed |
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC | 2009-02-19 | — | — | US | disclosed |
| EP-1999098-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007101864-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007101864-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | PPARD, PPARG, PPARA | PPARD 1/4885PPARG 2/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.